These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 30187275)

  • 21. Bone densitometry in pediatric patients treated with pamidronate.
    Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
    Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.
    Alcausin MB; Briody J; Pacey V; Ault J; McQuade M; Bridge C; Engelbert RH; Sillence DO; Munns CF
    Horm Res Paediatr; 2013; 79(6):333-40. PubMed ID: 23735642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
    Rauch F; Munns C; Land C; Glorieux FH
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical treatment of scoliosis in osteogenesis imperfecta with cement-augmented pedicle screw instrumentation.
    Yilmaz G; Hwang S; Oto M; Kruse R; Rogers KJ; Bober MB; Cahill PJ; Shah SA
    J Spinal Disord Tech; 2014 May; 27(3):174-80. PubMed ID: 24945295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
    Barros ER; Saraiva GL; de Oliveira TP; Lazaretti-Castro M
    J Pediatr Endocrinol Metab; 2012; 25(5-6):485-91. PubMed ID: 22876543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclic pamidronate therapy in children with osteogenesis imperfecta.
    Salehpour S; Tavakkoli S
    J Pediatr Endocrinol Metab; 2010; 23(1-2):73-80. PubMed ID: 20432809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome.
    Munns CF; Rauch F; Travers R; Glorieux FH
    J Bone Miner Res; 2005 Jul; 20(7):1235-43. PubMed ID: 15940378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS; Glorieux FH; Rauch F
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.
    Andiran N; Alikasifoglu A; Gonc N; Ozon A; Kandemir N; Yordam N
    J Pediatr Endocrinol Metab; 2008 Jan; 21(1):63-72. PubMed ID: 18404974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scoliosis in children with osteogenesis imperfecta: influence of severity of disease and age of reaching motor milestones.
    Engelbert RH; Uiterwaal CS; van der Hulst A; Witjes B; Helders PJ; Pruijs HE
    Eur Spine J; 2003 Apr; 12(2):130-4. PubMed ID: 12709850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pamidronate treatment of less severe forms of osteogenesis imperfecta in children.
    Zacharin M; Kanumakala S
    J Pediatr Endocrinol Metab; 2004 Nov; 17(11):1511-7. PubMed ID: 15570988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
    DiMeglio LA; Ford L; McClintock C; Peacock M
    Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
    Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
    J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
    Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
    J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
    Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
    J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
    Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
    Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.
    Aström E; Jorulf H; Söderhäll S
    Arch Dis Child; 2007 Apr; 92(4):332-8. PubMed ID: 17114205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.
    Zacharin M; Bateman J
    J Pediatr Endocrinol Metab; 2002 Feb; 15(2):163-74. PubMed ID: 11874181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.